A Phase II Randomized Study of Ixabepilone vs. Observation in Patients with Significant Residual Disease after Neoadjuvant Systemic Therapy for HER2/neu-negative Breast Cancer.

Trial Profile

A Phase II Randomized Study of Ixabepilone vs. Observation in Patients with Significant Residual Disease after Neoadjuvant Systemic Therapy for HER2/neu-negative Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Ixabepilone (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 15 Apr 2009 Bristol Myers Squibb reported as trial sponsor by M.D. Anderson Cancer Center.
    • 09 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top